In a study reported by Sarnaik et al., lifileucel was administered to patients with unresectable or metastatic melanoma, previously progressed through anti-PD-1 blockade (and targeted treatment if they had BRAF V600 mutation-positive disease) [77]. Here, PDCD1 is linked to metastatic melanoma.